TY - JOUR
T1 - Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer
T2 - A nested case-control study
AU - James, Rebecca E.
AU - Lukanova, Annekatrin
AU - Dossus, Laure
AU - Becker, Susen
AU - Rinaldi, Sabina
AU - Tjønneland, Anne
AU - Olsen, Anja
AU - Overvad, Kim
AU - Mesrine, Sylvie
AU - Engel, Pierre
AU - Clavel-Chapelon, Françoise
AU - Chang-Claude, Jenny
AU - Vrieling, Alina
AU - Boeing, Heiner
AU - Schütze, Madlen
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Trichopoulos, Dimitrios
AU - Palli, Domenico
AU - Krogh, Vittorio
AU - Panico, Salvatore
AU - Tumino, Rosario
AU - Sacerdote, Carlotta
AU - Rodríguez, Laudina
AU - Buckland, Genevieve
AU - Sánchez, Maria José
AU - Amiano, Pilar
AU - Ardanaz, Eva
AU - Bueno-de-Mesquita, Bas
AU - Ros, Martine M.
AU - Van Gils, Carla H.
AU - Peeters, Petra H.
AU - Khaw, Kay Tee
AU - Wareham, Nick
AU - Key, Timothy J.
AU - Allen, Naomi E.
AU - Romieu, Isabelle
AU - Siddiq, Afshan
AU - Cox, David
AU - Riboli, Elio
AU - Kaaks, Rudolf
PY - 2011/10
Y1 - 2011/10
N2 - Prediagnostic endogenous sex steroid hormone levels have well established associations with overall risk of breast cancer. While evidence toward the existence of distinct subtypes of breast cancer accumulates, few studies have investigated the associations of sex steroid hormone levels with risk of hormone receptor [estrogen receptor (ER) and/or progesterone receptor (PR)] defined breast cancer. In a case-control study nested within the EPIC cohort (European Prospective Investigation into Cancer and Nutrition), estradiol, testosterone, and sex hormone-binding globulin levels were measured in prediagnostic serum samples from postmenopausal women not using hormone replacement therapy at blood donation. A total of 554 women who developed invasive breast cancer with information on receptor status were matched with 821 control subjects. Conditional logistic regression models estimated breast cancer risk with hormone concentrations according to hormone receptor status of the tumor. Sex steroid hormones were associated with risks of not only ER+PR+ breast cancer [estradiol OR for highest vs. lowest tertile = 2.91 (95% CI: 1.62-5.23), P trend = 0.002; testosterone OR = 2.27 (95% CI: 1.35-3.81), P trend = 0.002] but also of ER-PR- breast cancer [estradiol OR = 2.11 (95% CI: 1.00-4.46), P trend = 0.05; testosterone OR = 2.06 (95% CI: 0.95-4.46), P trend = 0.03], with associations appearing somewhat stronger in the receptor-positive disease. Serum androgens and estrogens are associated with risks of both hormone receptor-negative as well as receptor-positive breast tumors. Further research is needed to establish through which molecular pathways, and during which evolutionary stages of development, androgens and estrogens can promote the occurrence of both receptor-positive and -negative clinical breast tumors.
AB - Prediagnostic endogenous sex steroid hormone levels have well established associations with overall risk of breast cancer. While evidence toward the existence of distinct subtypes of breast cancer accumulates, few studies have investigated the associations of sex steroid hormone levels with risk of hormone receptor [estrogen receptor (ER) and/or progesterone receptor (PR)] defined breast cancer. In a case-control study nested within the EPIC cohort (European Prospective Investigation into Cancer and Nutrition), estradiol, testosterone, and sex hormone-binding globulin levels were measured in prediagnostic serum samples from postmenopausal women not using hormone replacement therapy at blood donation. A total of 554 women who developed invasive breast cancer with information on receptor status were matched with 821 control subjects. Conditional logistic regression models estimated breast cancer risk with hormone concentrations according to hormone receptor status of the tumor. Sex steroid hormones were associated with risks of not only ER+PR+ breast cancer [estradiol OR for highest vs. lowest tertile = 2.91 (95% CI: 1.62-5.23), P trend = 0.002; testosterone OR = 2.27 (95% CI: 1.35-3.81), P trend = 0.002] but also of ER-PR- breast cancer [estradiol OR = 2.11 (95% CI: 1.00-4.46), P trend = 0.05; testosterone OR = 2.06 (95% CI: 0.95-4.46), P trend = 0.03], with associations appearing somewhat stronger in the receptor-positive disease. Serum androgens and estrogens are associated with risks of both hormone receptor-negative as well as receptor-positive breast tumors. Further research is needed to establish through which molecular pathways, and during which evolutionary stages of development, androgens and estrogens can promote the occurrence of both receptor-positive and -negative clinical breast tumors.
UR - http://www.scopus.com/inward/record.url?scp=80053912279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053912279&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-11-0090
DO - 10.1158/1940-6207.CAPR-11-0090
M3 - Article
C2 - 21813404
AN - SCOPUS:80053912279
VL - 4
SP - 1626
EP - 1635
JO - Cancer Prevention Research
JF - Cancer Prevention Research
SN - 1940-6207
IS - 10
ER -